Press release, 3 February 2023 at 9:00 a.m. (EET)

Nightingale Health Plc (“Nightingale Health”), a technology company promoting preventative health with its proprietary health risk detection platform, has combined its unique blood test results with genomic data in the latest release of its Livit by Nightingale Health mobile app. The introduction of genetic results into its consumer service follows the company’s announcement in January 2022 of expanding into genetics by acquiring Finnish genetics-testing company Negen Ltd. and launching an international excellence center of genomic data analysis.

Now, for the first time, the individual risk for heart disease and type 2 diabetes can be detected by using both the dynamic metabolic state of the body provided by the company’s proprietary blood test and static genetic data.

By combining information about how lifestyle affects the dynamic state of one’s health with the static inherited state, Livit can provide health risk assessments that are superior to any traditional health risk analysis. Moreover, the dynamic blood test data makes the combined health risk analysis actionable, since changes in lifestyle have a profound effect on health risks and the changes can be monitored with follow-up Livit blood tests.

The genetic results are calculated based on a raw genetic data file uploaded to the Livit service by the user. Initially, Livit users can enjoy the genetic feature free-of-charge, once they have purchased and done their first Livit Kit. Later the genetics feature in Livit will expand and also include the possibility of ordering a genetic test directly from Nightingale Health.

“By adding genetic risk information to Livit, we hope to help our users understand how both genetics and lifestyle are key to preventing common chronic diseases. We created an intuitive way for the user to see if they can “beat their genes” by adopting lifestyle changes that reduce their risk compared to people with similar genetic background,” shares Jeffrey Barrett, Nightingale Health’s Chief Scientific Officer.

“Our proprietary health risk detection platform is a world-leading solution to detect health risks and the platform empowers our customers to take early actions to manage and monitor their risks. Combining genetic data to our platform improves the risk detection capability even further by offering a novel solution that no other company in consumer genetics or traditional blood testing is providing. We are very excited to strengthen our core capability in health risk detection and bring this new feature to Livit users,” adds Teemu Suna, Nightingale Health’s CEO and one of the Founders.

For further information, please contact:

Teemu Suna, CEO

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.